.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

AAN 2020: Multiple Sclerosis Treatment Considerations

EP. 1: Multiple Sclerosis and Risk of COVID-19

May 22nd 2020

EP. 2: Disease-Modifying Therapies for MS During COVID-19

May 22nd 2020

EP. 3: AAN 2020: Real-World Data on Cladribine Tablets for MS

May 22nd 2020

EP. 4: Multiple Sclerosis: Takeaways From AAN 2020

May 22nd 2020

EP. 5: MS Treatment Optimization During COVID-19

May 22nd 2020

EP. 6: Treating Patients With MS During the COVID-19 Pandemic

May 22nd 2020

EP. 7: AAN 2020 Data Release: Ofatumumab for Relapsing MS

May 22nd 2020

EP. 8: Novel Oral Therapy for MS: AAN Data Updates

May 22nd 2020

EP. 9: The Future of Multiple Sclerosis Management

May 22nd 2020

Latest News

NeuroVoices: Michael Sughrue, MD, on the Future of Brain Mapping and Utilizing Advanced Technology

The Mobile Stroke Unit Paradigm Shift for EMS: Thomas Topley

American Stroke Association Publishes Updated Guidance for Intracerebral Hemorrhage

FDA Accepts New Drug Application for Intranasal Zavegepant to Treat Acute Migraine

View More News